US FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment - Reuters

The US FDA has approved a new hepatitis B drug developed by GSK, providing patients a potential opportunity to cease long-term treatment. This medication is administered via weekly injections over a six-month period. Clinical results indicate that some chronic hepatitis B patients successfully kept the virus under control even after stopping all antiviral medicines. This approval marks a significant step toward achieving a functional cure for individuals managing this chronic viral infection through medical intervention.